Positive

📈 MACTER: BUY Signal (8/10) – Transmission of Quarterly Report for the Period Ended September 30, 2025

⚡ Flash Summary

Macter International Limited (MACTER) reported its unconsolidated and consolidated condensed interim financial results for the period ended September 30, 2025. The company achieved a 28% increase in net turnover, reaching Rupees 2,769 million, with double-digit growth across all key categories. Profitability improved significantly, driven by strategic focus and effective execution in local and international markets. Earnings per share (EPS) rose to Rs. 3.41 compared to Rs. 2.03 in the same period last year, reflecting enhanced financial performance.

Signal: BUY 📈
Strength: 8/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 🚀 Net turnover increased by 28%, reaching Rupees 2,769 million.
  • 📈 EPS increased to Rs. 3.41 from Rs. 2.03 YoY.
  • 💰 Gross profit improved significantly, reaching Rupees 1,238 million.
  • 💊 Double-digit growth registered across key categories (prescription, institution, and export).
  • 🌱 Operating profit increased to Rupees 281 million.
  • ✅ Successfully commissioned Pre-Filled Syringe (PFS) and Pre-Filled Pen (PFP) manufacturing facilities.
  • 🔬 Launched innovative new products, including Hepanox, Empozin XR, Bismol Ultra, and Cobolmin SL.
  • 🌍 Consistent strategic focus on local and international markets.
  • 🤝 Effective execution of sales and marketing strategies.
  • 💼 Continuous investment in Research and Development, Manufacturing, and Commercial Excellence.
  • 🏭 Upgrading plants to meet international standards.
  • 🎯 Committed to providing greater therapeutic benefits and convenience for patients.
  • 👍 Acknowledged support from shareholders, customers, distributors, suppliers, financial institutions, and regulatory authorities.
  • 🌐 Plans to exploring new export markets.
  • ✨ Recognized the dedication and devotion of all employees.

🎯 Investment Thesis

BUY. Macter International has demonstrated strong financial performance with significant revenue and earnings growth. The commissioning of new manufacturing facilities and the launch of innovative products position the company for sustained growth. The strategic focus on local and international markets, along with effective execution of sales and marketing strategies, should drive continued success. Price Target: Rs. 4.50, Time Horizon: Medium Term.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

⏸️ ENGROH: HOLD Signal (6/10) – Transmission of Quarterly Report for the Period Ended September 30, 2025

⚡ Flash Summary

Engro Holdings reported a consolidated profit after tax (PAT) of PKR 86,152 million for the nine months ended September 30, 2025, significantly up from PKR 42,017 million in the same period last year. This translates to an EPS of PKR 34.89 versus PKR 13.21 last year. The major driver for this surge in profitability stems from the reversal of previously recognized impairment linked to thermal energy assets. Excluding this one-off impact, the PAT attributable to shareholders would stand at PKR 15,156 million, reflecting core earnings.

Signal: HOLD ⏸️
Strength: 6/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 🎉 PAT surged to PKR 86,152 million, a significant increase from PKR 42,017 million YoY.
  • 🚀 EPS soared to PKR 34.89 compared to PKR 13.21 YoY.
  • ♻️ The increase is largely due to a reversal of previously recognized impairment on thermal energy assets by PKR 54,174 million.
  • 📊 Excluding the impairment reversal, core earnings were PKR 15,156 million.
  • 📉 Standalone PAT declined to PKR 370 million from PKR 6,114 million YoY, with EPS dropping to PKR 0.31 from PKR 12.70.
  • 🔄 The standalone PAT drop is attributed to the transfer of income-generating investments to DH Partners and reduced dividends from Engro Corp.
  • 🏢 Engro Corporation became a wholly-owned subsidiary of the Company on January 1, 2025, with profit attributable to owners now reflecting 100% versus 39.97% last year.
  • 📈 Deodar Towers were consolidated on June 3, 2025, with assets and liabilities recorded at fair values of PKR 220,612 million and PKR 167,679 million, respectively.
  • 🏭 Fertilizer industry off-takes were impacted by weaker farmer economics and flood-related damage.
  • ⚡ EPTL dispatched a Net Electrical Output of 2,789 GWh, up from 2,573 GWh last year.
  • 🚫 No interim dividend was declared for 2025.
  • 🌱 The immediate priority remains to fund the remaining obligations of the towers transaction, retained earnings to support this investment.

🎯 Investment Thesis

HOLD. The company is fundamentally shifting. The one off impairment reversal impacts the earnings dramatically, but it’s hard to understand the go forward run rate. Recommendation: A Hold rating is warranted until core earnings trends become more evident and the impact of recent structural changes can be fully assessed. The absence of an interim dividend and the prioritization of tower transaction funding further support a Hold stance.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

📈 KOHP: BUY Signal (8/10) – Transmission of 1st Quarterly Report for the Period Ended 30-09-2025

⚡ Flash Summary

Kohinoor Power Company Limited (KOHP) reported a strong first quarter for the period ended September 30, 2025. Rental income significantly increased to Rs. 2.494 million compared to Rs. 1.362 million in the corresponding period last year. The company’s profit surged to Rs. 1.417 million from Rs. 0.182 million, leading to an EPS increase from Rs. 0.01 to Rs. 0.11. This impressive growth is attributed to increased rental income and strategic equity market investments.

Signal: BUY 📈
Strength: 8/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • ⬆️ Rental income soared to Rs. 2.494 million, a significant increase from Rs. 1.362 million YoY.
  • 💰 Net profit surged to Rs. 1.417 million, compared to Rs. 0.182 million in the previous year.
  • 📈 EPS improved dramatically to Rs. 0.11, up from Rs. 0.01 YoY.
  • 🏢 Increase in Rental Income and Equity Market investment boosted the Profit.
  • 👤 The Board of Directors consists of 6 male and 1 female director.
  • ✅ Audit Committee is Chaired by Mrs. Sadaf Kashif.
  • 🏦 Key bankers include Askari Bank Limited and MCB Bank Limited.
  • 🌐 Company website is www.kpcl.com.pk.
  • 🧾 Un-audited report for the quarter ended 30-09-2025.
  • 🏢 Registered office is located in Gulberg-II, Lahore.
  • 💼 Total Equity increased to Rs. 123.527 million from Rs. 122.109 million since June 30, 2025.
  • 💸 Cash and bank balances increased to Rs. 16.431 million from Rs. 13.198 million since June 30, 2025.
  • 🏭 Principal activity of the company is to generate and sell electric power.

🎯 Investment Thesis

BUY. KOHP presents a compelling investment opportunity based on its strong Q1 2026 performance. The significant growth in rental income, coupled with improved profitability and EPS, indicates a turnaround and positive growth trajectory. A price target of Rs. 2.00, reflecting a P/E ratio of 18.2, is justified given the improved EPS of 0.11. The time horizon is MEDIUM_TERM (12-18 months), anticipating continued growth and improved investor confidence.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

📈 LUCK: BUY Signal (7/10) – Transmission of Quarterly Report for the period ended – September 30, 2025

⚡ Flash Summary

Lucky Cement Limited’s Q1 FY2026 report reveals a company navigating a recovering Pakistani economy with cautious optimism. Consolidated gross revenue increased by 13.5% YoY to PKR 155.4 billion, driven by improved performance of the company and its subsidiaries, while consolidated net profit surged by 22.7% resulting in an EPS of PKR 15.01. The company is expanding both locally and internationally with an expansion of cement production capacity of 0.65 million tons per annum at Samawah, Iraq. However, the company faces challenges such as cheaper imports impacting its polyester, soda ash, and chemicals businesses.

Signal: BUY 📈
Strength: 7/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 📈 Consolidated gross revenue increased by 13.5% YoY, reaching PKR 155.4 billion.
  • 💰 Consolidated net profit increased by 22.7% YoY to PKR 23.6 billion.
  • ⭐ Earnings Per Share (EPS) increased by 22.7% to PKR 15.01.
  • 🏭 Domestic cement operations revenue increased by 15.2% YoY.
  • 🌍 Local sales volumes grew by 17.7%, outperforming the overall cement industry’s 15.0% growth.
  • 🇮🇶 Foreign cement operations in Iraq and Congo continued to drive profitability with improved margins.
  • 📉 Lucky Core Industries’ (LCI) net turnover decreased by 7% to PKR 28.6 billion due to lower revenues in some sectors.
  • 💊 Pharmaceuticals and Animal Health businesses of LCI showed growth, increasing by 25% and 22% respectively.
  • 🚗 Automobile sector demonstrated improved volumes, with an overall increase of 52% YoY.
  • 📱 Smartphone imports registered a substantial increase of 143% in volume and 114% in value YoY.
  • ⚡ The 660 MW Lucky Electric Power Company Limited (LEPCL) plant maintained 100% commercial availability.
  • ✔️ Pakistan’s domestic cement sales volumes increased by 15%, reaching 9.58 million tons.
  • 🌍 Exports also grew by 20.8% to 2.59 million tons.
  • ⛏️ Strategic expansion in copper and gold mining through National Resources (Pvt.) Limited (NRL).
  • 🌱 Cement production capacity expansion of 0.65 million tons per annum at Samawah, Iraq is progressing.

🎯 Investment Thesis

Lucky Cement is a BUY. The company has demonstrated strong financial performance in Q1 FY2026, with significant growth in revenue, net profit, and EPS. The company is well-positioned to capitalize on the recovering Pakistani economy, supported by improvements in industrial activity, fiscal discipline, and investor confidence. Key drivers for growth include the cement production capacity expansion in Iraq. The company’s EPS growth and industry performance make it an attractive investment.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

⏸️ BFBIO: HOLD Signal (6/10) – Transmission of Quarterly Financial Statements for the Period Ended 30-09-2025

⚡ Flash Summary

BFBIO’s Q3 2025 results show significant revenue growth, increasing by 75% compared to the same period last year, reaching Rs. 2,432 million. This growth is driven by strong performance in both in-market generic sales and institutional sales, attributed to increased volume from existing and new products after expanding commercial operations. Gross profit margin also improved, climbing to 43% due to changes in sales mix and better capacity utilization. Despite increased selling and distribution expenses, the company achieved a profit after tax of Rs. 160 million, representing a 38% increase; however, EPS saw a marginal decline due to an increase in the weighted average number of shares post-IPO.

Signal: HOLD ⏸️
Strength: 6/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 📈 Revenue surged by 75%, reaching Rs. 2,432 million compared to Rs. 1,386 million in Q3 2024.
  • 💊 In-market generic sales grew by 57% year-over-year.
  • 🏥 Institutional sales experienced a substantial increase of 209%.
  • 🏭 Line II commercial operations significantly contributed to volume growth.
  • 💰 Gross profit margin improved from 41% to 43%.
  • 🚀 Selling and distribution expenses increased by 133% to support topline growth.
  • 🏢 Administrative expenses rose by Rs. 28 million due to salaries and inflation.
  • ✅ Profit after tax increased by 38%, reaching Rs. 160 million compared to Rs. 115 million.
  • 📉 Earnings per share (EPS) slightly decreased to Rs. 1.81 from Rs. 1.82.
  • 📃 Weighted average number of shares increased to 88.3 million from 63.3 million post-IPO.
  • 🏭 Increased capacity utilization led to better absorption of factory overheads.
  • 🌱 Company listed on the Pakistan Stock Exchange on October 21, 2024.

🎯 Investment Thesis

Based on the Q3 2025 results, a HOLD recommendation is appropriate. While the company demonstrates strong revenue growth and improved gross profit margin, the increased operating expenses and EPS dilution raise concerns. The potential for continued growth in sales volume and effective cost management could drive future profitability. Before upgrading to a BUY, further evidence of sustained EPS growth and improved operational efficiencies are needed. Before downgrading to SELL, cost control and EPS dilution need to be closely monitored.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

📈 GCIL: BUY Signal (8/10) – Transmission of 1st Quarterly Accounts – GHANI CHEMICAL INDUSTRIES LIMITED

⚡ Flash Summary

Ghani Chemical Industries Limited (GCIL) reported an impressive Q1 2025, showcasing significant growth despite challenging economic conditions. Sales increased to Rs. 2,169 million from Rs. 2,037 million in the same period last year, driven by increased sales volumes and improved pricing. This resulted in a surge in gross profit to Rs. 909 million from Rs. 636 million. Profit after taxation also saw a substantial increase to Rs. 528 million from Rs. 303 million, leading to higher earnings per share of Rs. 0.93 compared to Rs. 0.61 last year.

Signal: BUY 📈
Strength: 8/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 🚀 Sales increased to Rs. 2,169 million from Rs. 2,037 million, a ~6.5% increase YoY.
  • 📈 Gross profit surged to Rs. 909 million from Rs. 636 million, representing a ~43% increase YoY.
  • 💰 Profit after taxation jumped to Rs. 528 million from Rs. 303 million, a ~74% increase YoY.
  • ⭐ Earnings per share (EPS) rose to Rs. 0.93 from Rs. 0.61, a ~52% increase YoY.
  • 🏭 Enhanced operational efficiency and optimized plant performance boosted profitability.
  • 🎯 Focus on process improvement and higher capacity utilization contributed to lower per-unit production costs.
  • 🌱 The company is expanding into new business areas, establishing a 450 MT capacity LPG Storage and Filling Plant.
  • 🤝 GCIL has signed an MOU with a leading Pakistani energy company for capturing and processing cold vent/exhaust gases, promoting sustainability.
  • 💸 Distribution costs significantly increased to Rs. 132.6 million from Rs. 39.48 million.
  • 💼 Administrative expenses also rose to Rs. 85.9 million from Rs. 64.4 million.
  • 🏦 Finance costs increased to Rs. 137.777 million from Rs. 114.794 million.
  • 💹 Net cash used in operating activities stood at (Rs. 37.513) million compared to Rs. 327.191 million generated last year.
  • 👍 Basic/diluted combined earnings per share is Rs. 0.93 compared to Rs. 0.61 previously.

🎯 Investment Thesis

GCIL is a BUY. The company’s strong Q1 2025 performance, driven by increased sales and improved profitability, demonstrates effective management and operational efficiencies. The expansion into new business areas, along with sustainability initiatives, positions the company for future growth. However, the negative operating cash flow needs to be monitored closely.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

⏸️ CRTM: HOLD Signal (6/10) – Transmission of Quarterly Report for the Period Ended September 30, 2025

⚡ Flash Summary

Crescent Textile Mills Limited (CRTM) reported results for the first quarter ended September 30, 2025. The company experienced revenue growth primarily due to a change in strategy focused on attracting value-added business with better margins. The loss after tax significantly decreased due to improved gross margins and reduced finance costs. Despite prevailing challenges like depressed demand and high energy costs, the company is optimistic about future sustainability and growth through new customers, markets, and investments in green energy.

Signal: HOLD ⏸️
Strength: 6/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 📈 Revenue increased by 21% to PKR 4,840 million in Q1 2026 from PKR 3,991 million in Q1 2025.
  • 💰 Cost of sales increased by 22% to PKR 4,249 million in Q1 2026.
  • ✅ Gross profit increased by 14% to PKR 591 million in Q1 2026.
  • 🚚 Distribution costs increased by 25% to PKR 231 million.
  • 🏢 Administrative expenses increased by 14% to PKR 137 million.
  • 📉 Finance cost decreased by 43% to PKR 215 million.
  • ✅ Loss after tax significantly decreased by 85% to PKR 26 million.
  • ⚠️ Depressed demand and pressure on sales prices remain significant challenges.
  • 🌱 The company is focused on tapping into new customers and markets.
  • 🔋 Investments in green energy are underway to reduce energy costs.
  • 🤝 The Board acknowledged the management’s hard work and the contributions of all stakeholders.
  • 📊 Basic and diluted loss per share improved to (0.26) rupees compared to (1.66) rupees in the same quarter last year.
  • 💵 Cash generated from operations decreased from 368.169 million to 19.168 million, signaling a worrying trend

🎯 Investment Thesis

HOLD. While the company has shown improvement in revenue and reduced losses, persistent challenges and a negative EPS necessitate a cautious approach. A ‘Hold’ rating is justified until sustained profitability is demonstrated, and the effectiveness of cost optimization and green energy initiatives is confirmed. There is uncertainty that must be resolved before recommending a buy.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

📈 HPL: BUY Signal (7/10) – Transmission of Quarterly Report for the Nine Months Period Ended 30 September 2025

⚡ Flash Summary

Hoechst Pakistan Limited (HPL) reported unconsolidated interim financial statements for the nine months ended September 30, 2025. Net sales increased by 20% to Rs. 24,569 million compared to the same period last year, driven by growth in Cardiovascular, Consumer Healthcare, and Diabetes portfolios. Gross profit margin improved to 35% from 31% due to renegotiation of supply prices and production efficiency. Profit after tax significantly increased to Rs. 2,220 million from Rs. 1,205 million in 2024, although other expenses increased due to adverse exchange rate movements.

Signal: BUY 📈
Strength: 7/10
Sentiment: POSITIVE
Time Horizon: SHORT_TERM

📌 Key Takeaways

  • 📈 Net sales grew by 20% reaching Rs. 24,569 million.
  • 💰 Gross profit surged to Rs. 8,667 million.
  • 📊 Gross margin improved significantly from 31% to 35%.
  • ⚙️ Operating profit increased substantially to Rs. 3,959 million.
  • 📉 Finance costs slightly decreased to Rs. (76) million.
  • ✅ Profit after tax jumped to Rs. 2,220 million.
  • ⭐ Earnings per share rose to Rs. 230.14.
  • ⬆️ Distribution and marketing expenses increased to 14% of net sales.
  • ⬇️ Administrative expenses decreased to 3% of net sales.
  • exchange loss increased to Rs. 272 million.
  • 🌱 H-Pack Wellness (Private) Limited contributed Rs. 13.8 million in revenue and reported net loss of Rs. 8.7 million.
  • 💸 Investment in H-Pack Wellness (Private) Limited is Rs. 20 million.
  • 🌎 Geographic revenue mix: Pakistan (Rs. 23,385 million), Afghanistan (Rs. 1,183 million).

🎯 Investment Thesis

HPL showcases robust financial performance with strong sales and profit growth. The improvement in gross margin due to cost management initiatives makes the stock favorable. The expansion into wellness product through H-Pack is a strategic move. Recommend a BUY rating based on these factors. The price target is based on sector peers, with a short term horizon, as the company is in expansion mode.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

📈 FEROZ: BUY Signal (7/10) – Transmission of Quarterly Financial Statements for the Period Ended 30-09-2025

⚡ Flash Summary

Ferozsons Laboratories Limited (FEROZ) reported its condensed interim financial information for the three months ended September 30, 2025. On a consolidated basis, net sales increased by 31% to Rs. 5.94 billion. The company’s gross profit margin improved to 41% from 39% in the same period last year, attributed to a shift in sales mix away from lower-margin institutional sales. Earnings per share (EPS) increased to Rs. 4.20, compared to Rs. 3.23 in the same period last year.

Signal: BUY 📈
Strength: 7/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 🚀 Consolidated net sales increased by 31% to Rs. 5.94 billion.
  • 📈 Standalone net sales grew by 16% to Rs. 3.88 billion.
  • 💊 In-market generic sales increased by 21%.
  • 📉 Institutional sales of generics and medical devices decreased by 1%.
  • 💰 Gross Profit (GP) margin improved to 41% from 39%.
  • 📊 Selling and distribution expenses increased by 30%.
  • 💸 Administrative expenses increased by 16% due to inflationary impact.
  • 📉 Finance costs decreased by 50% due to reduced policy rate by State Bank of Pakistan.
  • 👍 Profit before tax grew by 50%.
  • 📈 Profit after tax increased by 30%.
  • 🧾 Effective tax rate closed at 39%, compared to 27% last year, due to change in tax regime for export sales.
  • ⭐ Standalone earnings per share (EPS) closed at Rs. 4.20, compared to Rs. 3.23 last year.
  • 🧪 BF Biosciences Limited sales increased by 75% to Rs. 2.43 billion.
  • 💸 BF Biosciences Limited profit after tax increased by 38% to Rs. 160 million.

🎯 Investment Thesis

BUY: Ferozsons Laboratories demonstrates strong revenue growth and improved profitability. The company’s strategic shift towards higher-margin sales and efficient cost management makes it an attractive investment. Price Target: Rs. 7.50. Time Horizon: Medium Term.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

📈 BNL: BUY Signal (8/10) – Transmission of Quarterly Report for the Period Ended

⚡ Flash Summary

Bunnys Limited’s Q1 2025 report reveals an 11.76% increase in revenue compared to Q1 2024, reaching Rs. 2,012.18 million. The gross profit margin improved significantly to 29.72% from 25.12% year-over-year. Profit after tax surged substantially to Rs. 162.13 million, a notable rise from Rs. 30.13 million in the prior year. Earnings per share (EPS) also increased significantly to Rs. 2.43 from Rs. 0.45, indicating a strong improvement in profitability.

Signal: BUY 📈
Strength: 8/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM

📌 Key Takeaways

  • 🚀 Revenue increased by 11.76% year-over-year, reaching Rs. 2,012.18 million.
  • 📈 Gross profit margin improved to 29.72% from 25.12%.
  • 💰 Profit after tax increased significantly to Rs. 162.13 million from Rs. 30.13 million.
  • ⭐ Earnings per share (EPS) increased to Rs. 2.43 from Rs. 0.45.
  • 📊 Operating profit increased to Rs. 234.49 million from Rs. 133.30 million.
  • 🍞 Strong demand across key product categories drove improved results.
  • 🎯 Enhanced product portfolio focusing on health-oriented and value-added food items.
  • 📣 Effective brand and distribution strategies boosted financial performance.
  • ⚙️ Emphasis on cost optimization, process efficiency, and quality assurance contributed to improved margins.
  • 🌱 Net profit ratio increased to 8.06% against a net ratio of 1.67% of the same quarter last year.
  • 🏦 Finance costs decreased slightly due to lower markup rates.
  • 🏭 The company is continuously updating its plant and equipment with cutting-edge technology.
  • 🤝 Acknowledgement to stakeholders including shareholders and bankers.
  • 🔒 No major changes in commitments affecting the financial position.
  • 🌐 Website: www.bunnys.com.pk

🎯 Investment Thesis

BUY. Bunnys Limited shows robust financial performance with significant improvements in revenue, profitability, and EPS. The company’s strategic initiatives, including product portfolio enhancement and cost optimization, contribute to sustained growth. A price target of Rs. 100.00, based on a P/E multiple of 41x, is justified given the company’s growth trajectory. Time horizon: Medium Term (12-18 months). The increase in earnings should attract investor attention and drive the stock price higher.

View Original PDF

Disclaimer: AI-generated analysis. Not financial advice.

Written by: FoxLogica News Analysis

Published on: November 6, 2025

+ More